𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody

✍ Scribed by Gavin W. L. Denton; Lindy G. Durrant; Jack D. Hardcastle; Eric B. Austin; Herb F. Sewell; R. Adrian Robins

Publisher
John Wiley and Sons
Year
1994
Tongue
French
Weight
600 KB
Volume
57
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

A human monoclonal anti‐idiotypic antibody (105AD7) has been developed which mimics a colorectal‐tumour‐associated antigen and induces cellular anti‐colorectal tumour immune responses in animals. Thirteen patients with advanced colorectal cancer were immunized with 105AD7 and their survival was compared with that of a contemporary group of unimmunized patients with similar disease status. No toxicity related to anti‐idiotype immunization was seen. Cellular responses to anti‐idiotypic immunization were indicated by lymphocyte proliferation to gp72‐positive tumour cells, and production of interleukin‐2; anti‐tumour antibodies were not detected. Median survival following diagnosis of advanced disease of immunized patients was 12 months, compared with 4 months in unimmunized patients. The improved survival of immunized patients in this study without associated toxicity suggests that 105AD7 immunization may have considerable potential for immunotherapy of colorectal cancer. © Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Improved tumor targeting of rhenium-186-
Improved tumor targeting of rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2–23
✍ Carl V. Hamby; Marco Chinol; Christopher J. Palestro; Ciro Manzo; Soldano Ferron 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 101 KB

Because of its high-energy beta emissions and imageable gamma emissions, 186 Re represents an attractive isotope to radiolabel monoclonal antibodies (MAbs) recognizing human tumor-associated antigens (TAAs) for radioimmunoscintigraphy (RIS) and radioimmunotherapy (RIT) of patients with malignant dis

Biodistribution of a monoclonal antibody
Biodistribution of a monoclonal antibody-methotrexate conjugate (791T/36-MTX) in patients with colorectal cancer
✍ K. C. Ballantyne; A. C. Perkins; M. V. Pimm; M. C. Garnett; Jane A. Clegg; N. C. 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 French ⚖ 547 KB

The monoclonal antibody (MAb) 791T/36 which has previously been shown to localise in colorectal cancer has been conjugated to methotrexate (MTX) for potential use as a chemotherapeutic agent in malignant disease. To examine its biodistribution and tumour localisation, 16 patients with primary colore

Inhibition of bispecific monoclonal anti
Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes
✍ Cor H. J. Lamers; Jan W. Gratama; Sven O. Warnaar; Gerrit Stoter; Reinder L. H. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 743 KB

T lymphocytes of 8 patients with ovarian cancer were targeted to the tumor cells using F(ab')2 fragments of a bispecific monoclonal antibody (bsAb), specific for CD3 (a component of the T lymphocyte receptor for antigen) and for the folate receptor MOv I 8 (overexpressed by ovarian carcinoma cells)

Induction of cellular immune responses b
Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791tgp72 antigen expressed on colorectal, gastric and ovarian human tumours
✍ Lindy G. Durrant; Mark Doran; Eric B. Austin; R. Adrian Robins 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 525 KB

There is accumulating evidence that cellular rather than antibody responses are more effective for tumour rejection. It is therefore important to screen anti-idiotypic (anti-id) antibodies for their ability to stimulate anti-tumour T-cell responses. The human anti-id monoclonal antibody (MAb) I05AD7